Retatrutide (LY3437943): Triple GLP-1/GIP/Glucagon Receptor Agonist — Research Applications and Mechanism
Retatrutide (developmental code LY3437943) is a synthetic peptide research compound developed by Eli Lilly functioning as a simultaneous agonist at three distinct receptor systems: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This triple receptor co-activation profile distinguishes retatrutide from all previously studied compounds in its class and makes it one of the most pharmacologically complex metabolic research peptides currently available for in-vitro study.
For researchers studying multi-receptor pharmacology, energy homeostasis signaling, and incretin axis biology, retatrutide represents a uniquely powerful experimental tool.
For in-vitro and preclinical laboratory research use only. Not for human consumption.
Molecular Profile
- Compound name: Retatrutide
- Developmental code: LY3437943
- CAS number: 2381089-83-2
- Molecular weight: ~4,531 g/mol
- Structure: Synthetic peptide conjugated to a fatty diacid moiety for extended pharmacokinetic half-life
- Receptor targets: GLP-1R, GIPR, GCGR (triple co-agonist)
The fatty diacid conjugation is structurally significant for research purposes — it extends circulation time compared to native peptides and enables once-weekly dosing schedules in in-vivo research models, a pharmacokinetic characteristic that has informed study design across the preclinical and clinical research programs.
Receptor Binding Profile
Understanding retatrutide’s research profile requires examining each receptor system independently before considering their combined activation.
GLP-1 Receptor (GLP-1R)
Retatrutide activates GLP-1R with potency approximately 0.4× that of native GLP-1. Compared to the corresponding endogenous hormones, retatrutide is less potent at GLP-1R by a factor of 0.4. In research models, GLP-1R activation is associated with pancreatic beta-cell pathway signaling, incretin axis modulation, and gastric motility regulation. These are established research areas with extensive published literature.
GIP Receptor (GIPR)
GIPR agonism is retatrutide’s most potent receptor interaction. Retatrutide is more potent at GIPR by a factor of 8.9 compared to endogenous GIP. This pronounced GIPR activity distinguishes retatrutide from semaglutide (GLP-1R mono-agonist) and aligns it mechanistically with tirzepatide (dual GLP-1R/GIPR), while adding a third receptor dimension.
Glucagon Receptor (GCGR)
GCGR activation is the key differentiator of the triple agonist class. Retatrutide is less potent at GCGR by a factor of 0.3 compared to native glucagon. In research models, GCGR engagement is studied for hepatic glucose production regulation, thermogenesis signaling, and energy expenditure pathway research. The simultaneous activation of GCGR alongside GLP-1R and GIPR creates what researchers have described as a receptor polypharmacology model — where each pathway modulates the others.
Preclinical Research Data
A 2022 preclinical pharmacology paper in Cell Metabolism by Coskun and colleagues from Eli Lilly described LY3437943’s receptor binding profile, noting balanced GCGR and GLP-1R activity with more prominent GIPR activity, and documented that in diet-induced animal models, body-weight reduction was augmented by glucagon receptor-mediated increases in energy expenditure layered on top of GIPR and GLP-1R-driven calorie intake reduction. The same paper reported persistent body-weight reduction lasting 43 days post-dose in animal models, suggesting a pharmacodynamically durable profile.
The sustained post-dose effect observed in preclinical models is a pharmacokinetic characteristic of particular interest for researchers studying receptor occupancy dynamics and the relationship between half-life extension and downstream signaling duration.
Comparative preclinical data with tirzepatide showed augmented effects in retatrutide-treated models, attributed specifically to the added GCGR activation dimension — providing researchers with a useful experimental comparison between dual and triple receptor co-activation profiles.
Published Clinical Research Data
Retatrutide has advanced through Phase 2 clinical investigation with published data in peer-reviewed journals, providing researchers with a substantial published evidence base for in-vitro study context.
Phase 2 — New England Journal of Medicine (2023)
The Jastreboff et al. Phase 2 trial published in the New England Journal of Medicine remains the primary published dataset for retatrutide. The study examined receptor agonist activity across dose ranges in a 48-week period.
Phase 3 — TRIUMPH trials (ongoing through 2026)
Seven Phase 3 trials evaluating the investigational once-weekly compound in metabolic and body-weight research are expected to complete in 2026. The TRIUMPH-4 trial released positive topline results in December 2025, with detailed results to be presented at a future medical meeting.
Liver biology research — Nature Medicine (2024)
A Phase 2a trial published in Nature Medicine examined retatrutide in the context of hepatic steatosis biology. Results showed up to 82% reduction in liver fat in the studied population, making the GCGR-mediated hepatic pathway a significant area of ongoing research interest.
Structural biology — Nature (2024)
Structural insights into retatrutide’s triple receptor co-activation mechanism were published, providing molecular-level understanding of how a single peptide molecule simultaneously engages three distinct receptor binding sites — a research finding with implications for multi-receptor pharmacology study design.
Research Applications
Retatrutide is studied in laboratory settings across several research pathways:
Multi-receptor pharmacology
As the most pharmacologically complex triple agonist available for research, LY3437943 enables study of simultaneous GLP-1R/GIPR/GCGR co-activation in ways not possible with mono or dual agonists. Researchers can examine receptor cross-talk, pathway interaction, and the contribution of individual receptor components by comparing retatrutide activity profiles against tirzepatide and semaglutide in the same experimental systems.
Incretin axis biology
The compound’s balanced GLP-1R and pronounced GIPR activity makes it useful for studying incretin axis regulation at multiple receptor nodes simultaneously.
Hepatic pathway research
GCGR-mediated hepatic glucose production pathway studies benefit from retatrutide’s selective GCGR activity profile — potent enough for meaningful receptor engagement while operating at a lower potency than native glucagon.
Comparative receptor studies
Retatrutide serves as a natural comparator compound in studies examining mono vs dual vs triple agonist receptor activation profiles — a research design that has become increasingly common as the triple agonist class has expanded.
Verification and Quality Standards
PYXAX supplies retatrutide as a lyophilized research compound with independent third-party verification before listing.
Every production lot undergoes:
- Purity by HPLC — chromatographic purity percentage
- Identity by LC-MS — mass spectrometric identity confirmation
- Endotoxin testing (USP 85-style)
- Heavy metals (ICP-MS)
- QR-verified COA — independently verifiable at the testing laboratory’s portal
Lot-specific Certificates of Analysis are published in the PYXAX COA Library before compounds ship. Researchers can verify results independently through ILS Laboratories’ public verification portal or Janoshik Analytical’s searchable database.
Research Citations
- Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist — receptor binding study. Cell Metabolism. 2022;34(9):1234–1247.
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide — Phase 2 Trial. N Engl J Med. 2023;389:514–526.
- Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease — Phase 2a trial. Nature Medicine. 2024.
- Zhao X, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Nature. 2024.
Sourcing and Availability
PYXAX retatrutide research compound is available in the following lot sizes for qualified laboratory researchers:
- Retatrutide 5mg
- Retatrutide 10mg
- Retatrutide 20mg
All PYXAX compounds are supplied strictly for in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use. Not for diagnostic procedures. For qualified laboratory researchers only. These statements have not been evaluated by the FDA.